Top View
- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection Among Women in Africa: a Randomized Trial
- Once-Daily Atazanavir/Ritonavir Versus Twice-Daily
- Role of Lopinavir/Ritonavir in the Treatment of Covid-19: a Review of Current Evidence, Guideline Recommendations, and Perspectives
- Kaletra Product Monograph
- Identification of Existing Pharmaceuticals and Herbal Medicines As Inhibitors of SARS-Cov-2 Infection
- Drug Resistance of Human Immunodeficiency Virus and Overcoming It by Natural Products
- Ccr5 Antagonists in the Treatment of Treatment-Naïve Patients Infected with Ccr5 Tropic Hiv-1
- SYMTUZA® (Darunavir, Cobicistat, Emtricitabine, and Tenofovir
- Lopinavir/Ritonavir (LPV/R, Kaletra) (Last Updated April 7, 2021; Last Reviewed April 7, 2021)
- Lopinavir and Ritonavir Oral Pellets 40 Mg/10 Mg
- Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral
- Tea Polyphenols As Natural Products for Potential Future Management of HIV Infection
- Appropriate Use and Safety Edits
- ATRIPLA Safely and Effectively
- Antiviral Effects of Green Tea EGCG and Its Potential Application Against COVID-19
- New Data on New HIV Drug(Oral CCR5 Receptor Antagonist)
- HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use SUSTIVA Safely and Effec
- Dual Therapy with Lopinavir and Ritonavir Plus Lamivudine
- Descovy, INN-Emtricitabine / Tenofovir Alafenamide
- (DHPC): Kaletra (Lopinavir/Ritonavir) Oral Solution, 2 Bottle Pack Containing
- Lopinavir/Ritonavir (Kaletra®)
- How to Choose a PEP Regimen?
- ANTIRETROVIRAL THERAPY for HIV INFECTION in INFANTS and CHILDREN: 102 TOWARDS UNIVERSAL ACCESS Manufacturing Practices
- Application for Inclusion of Lopinavir /Ritonavir Oral Granules (LPV/R) Formulation on WHO Model List of Essential Medicines for Children
- Lopinavir/Ritonavir Plus Lamivudine and Abacavir Or Zidovudine Dose Ratios for Paediatric Fixed-Dose Combinations
- Mechanisms of Ccr5 Agonist/Antagonist Inhibition of Hiv-1
- HIV Post-Exposure Prophylaxis (PEP)
- ISENTRESS (Raltegravir) Film-Coated Tablets, for Oral Use Been Reported
- Atazanavir / Ritonavir Versus Lopinavir / Ritonavir-Based Combined Antiretroviral Therapy (Cart) for HIV-1 Infection: a Systematic Review and Meta-Analysis
- Kaletra, INN-Lopinavir, Ritonavir
- Atazanavir (Reyataz)
- Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: a Systematic Review
- Fact Sheet on Lopinavir and Ritonavir (LPV/R) Oral Pellets
- (RAL) Granules As Suspension to an Infant
- Application for Inclusion of Abacavir, Lamivudine, Lopinavir, and Ritonavir (ABC/3TC/LPV/R) Formulation in WHO Model List of Essential Medicines for Children
- Lopinavir/Ritonavir Mylan, INN-Lopinavir/Ritonavir
- Page: Treatment-Drugs
- Reference ID: 4173147
- KALETRA (Lopinavir and Ritonavir)
- Lopinavir-Ritonavir Is Not an Effective Inhibitor of the Main Protease Activity of SARS-Cov-2 in Vitro
- Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases
- Natural Products As Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders
- Identification of Novel Compounds Against Three Targets of SARS Cov-2 Coronavirus by Combined Virtual Screening and Supervised Machine Learning
- Lopinavir/Ritonavir Or Efavirenz Plus Two
- Antiviral Activity of Green Tea and Black Tea Polyphenols in Prophylaxis and Treatment of COVID-19 a Review
- KALETRA® (Lopinavir/Ritonavir) Capsules
- Small Molecules of Natural Origin As Potential Anti-HIV Agents: a Computational Approach
- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV
- Risk Management Plan Lopinavir / Ritonavir RMP Version 2.0 Pg. 70 VI
- 2.0 Protocol Synopsis